The Englander Institue's lab has developed miniature 3D cellular structures, called organoids. that imitate a patient’s tumor. These models are used to predict drug resistance and help direct the best line of therapy with the assistance of the EIPM High-Throughput Drug Screening Platform.
Our diverse biobank of patient-derived organoid models are a valuable resource for researchers and clinicians. In addition to banking tumor organoids, our team has assembled an impressive drug compound screening platform to better understand and treat each patient's disease.
